原发性硬化性胆管炎
发育不良
炎症性肠病
FOXP3型
医学
免疫系统
炎症
结直肠癌
免疫学
抗原
癌症
内科学
胃肠病学
疾病
作者
Dustin G. Shaw,Raúl Aguirre‐Gamboa,Marcos C. Vieira,Saideep Gona,Nicholas DiNardi,Anni Wang,Anne Dumaine,Jody Gelderloos-Arends,Zachary M. Earley,Katherine Meckel,Cezary Ciszewski,Anabella Castillo,Kelly Monroe,Joana Torres,Shailja C. Shah,Jean‐Frédéric Colombel,Steven H. Itzkowitz,Rodney D. Newberry,Russell D. Cohen,David T. Rubin
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2023-06-01
卷期号:29 (6): 1520-1529
被引量:41
标识
DOI:10.1038/s41591-023-02372-x
摘要
Abstract Primary sclerosing cholangitis (PSC) is an immune-mediated disease of the bile ducts that co-occurs with inflammatory bowel disease (IBD) in almost 90% of cases. Colorectal cancer is a major complication of patients with PSC and IBD, and these patients are at a much greater risk compared to patients with IBD without concomitant PSC. Combining flow cytometry, bulk and single-cell transcriptomics, and T and B cell receptor repertoire analysis of right colon tissue from 65 patients with PSC, 108 patients with IBD and 48 healthy individuals we identified a unique adaptive inflammatory transcriptional signature associated with greater risk and shorter time to dysplasia in patients with PSC. This inflammatory signature is characterized by antigen-driven interleukin-17A (IL-17A) + forkhead box P3 (FOXP3) + CD4 T cells that express a pathogenic IL-17 signature, as well as an expansion of IgG-secreting plasma cells. These results suggest that the mechanisms that drive the emergence of dysplasia in PSC and IBD are distinct and provide molecular insights that could guide prevention of colorectal cancer in individuals with PSC.
科研通智能强力驱动
Strongly Powered by AbleSci AI